How to buy CRISPR Therapeutics shares
Own CRISPR Therapeutics shares in just a few minutes.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
CRISPR Therapeutics AG is a biotechnology business with stocks listed in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$109.83 – a decrease of 7.07% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in CRISPR Therapeutics
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for CRISPR Therapeutics. Find the share by name or ticker symbol: CRSP. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CRISPR Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$109.83, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of CRISPR Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of CRISPR Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- CRISPR Therapeutics key stats
- Compare share trading platforms
- Is CRISPR Therapeutics stock a buy or sell?
- CRISPR Therapeutics performance over time
- Can I short CRISPR Therapeutics shares?
- CRISPR Therapeutics's financials
- How volatile are CRISPR Therapeutics shares?
- Does CRISPR Therapeutics pay a dividend?
- Other common questions
CRISPR Therapeutics share priceUse our graph to track the performance of CRSP stocks over time.
CRISPR Therapeutics shares at a glance
|52-week range||US$67.38 - US$220.2|
|50-day moving average||US$116.1077|
|200-day moving average||US$138.5717|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$0.316|
Compare share trading platforms to buy stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy CRISPR Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
CRISPR Therapeutics price performance over time
|1 week (2021-06-14)||-14.70%|
|1 month (2021-05-21)||-4.97%|
|3 months (2021-03-19)||-15.26%|
|6 months (2020-12-21)||-34.17%|
|1 year (2020-06-19)||58.99%|
|2 years (2019-06-21)||141.86%|
|3 years (2018-06-21)||68.61%|
Is CRISPR Therapeutics under- or over-valued?
Valuing CRISPR Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CRISPR Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CRISPR Therapeutics's EBITDA
CRISPR Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$2.9 million.
The EBITDA is a measure of a CRISPR Therapeutics's overall financial performance and is widely used to measure a its profitability.
CRISPR Therapeutics financials
|Revenue TTM||US$1.1 million|
|Gross profit TTM||US$-266,227,000|
|Return on assets TTM||-16.67%|
|Return on equity TTM||-29.15%|
|Market capitalisation||US$10 billion|
TTM: trailing 12 months
Shorting CRISPR Therapeutics shares
There are currently 3.3 million CRISPR Therapeutics shares held short by investors – that's known as CRISPR Therapeutics's "short interest". This figure is 14.2% down from 3.9 million last month.
There are a few different ways that this level of interest in shorting CRISPR Therapeutics shares can be evaluated.
CRISPR Therapeutics's "short interest ratio" (SIR)
CRISPR Therapeutics's "short interest ratio" (SIR) is the quantity of CRISPR Therapeutics shares currently shorted divided by the average quantity of CRISPR Therapeutics shares traded daily (recently around 1.3 million). CRISPR Therapeutics's SIR currently stands at 2.47. In other words for every 100,000 CRISPR Therapeutics shares traded daily on the market, roughly 2470 shares are currently held short.
However CRISPR Therapeutics's short interest can also be evaluated against the total number of CRISPR Therapeutics shares, or, against the total number of tradable CRISPR Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CRISPR Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 CRISPR Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0505% of the tradable shares (for every 100,000 tradable CRISPR Therapeutics shares, roughly 51 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CRISPR Therapeutics.
Find out more about how you can short CRISPR Therapeutics stock.
CRISPR Therapeutics share dividends
We're not expecting CRISPR Therapeutics to pay a dividend over the next 12 months.
CRISPR Therapeutics share price volatility
Over the last 12 months, CRISPR Therapeutics's shares have ranged in value from as little as US$67.38 up to US$220.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CRISPR Therapeutics's is 2.2459. This would suggest that CRISPR Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CRISPR Therapeutics overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in the development of regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. It also has a strategic partnership with Nkarta, Inc. to research, develop, and commercialize CRISPR/Cas9 gene-edited cell therapies for cancer. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Frequently asked questions
More guides on Finder
Staple items worth a splurge and how you can grab a cheeky 30% off all of them
We've got a cheeky 30% off THE ICONIC so here are the staple items worth a splurge because the savings are too damn good.
THE ICONIC x Finder: Huge 30% off sale + 5 things to shop right now
THE ICONIC's massive sale is exclusive to Finder members and applies to over 40,000 must-have items.
Why the BHP, Rio and FMG share prices are rising
Shares in mining giants BHP, Rio Tinto and Fortescue Metals have climbed between 10%-16% in the last 6 months.
Finder Daily Deals: The 5 best Prime Day deals in Australia today
Today's best Finder Daily deals include: $1,000 off Dell gaming laptops, 30% off kids toys, win $10,000 with Optus.
eBay EOFY sales: Best deals from Apple, KitchenAid and more
Score up to 65% off best-selling products with these top end of financial year offers.
Thinking about teeth aligners? Here’s how to make them more affordable
SPONSORED: Perfect teeth could be in closer reach than you think.
Your first look at the Billie Eilish x Air Jordan 1 sneaker collab
Featuring Billie's signature shade, here's what you need to know if you want to cop these kicks.
Amazon Prime Day 2021: Don’t miss these deals on 21 June
Amazon Prime Day is returning to Australia in the first half of 2021. Here are six online deals you need to know about.
How to buy TitanSwap (TITAN) in Australia
This guide will show you step-by-step instructions on how to buy the TitanSwap (TITAN) token as well as a list of exchanges you can trade it on.
Canterbury Bulldogs vs St George Illawarra Dragons NRL: Start time and watch free
The one-win Bulldogs return after a bye, hopefully refreshed and ready to meet the Dragons.
Ask an Expert